BK241074 · One Lambda, Inc. West Hills, CA · QUK · Aug 1, 2024 · Immunology
Device Facts
Record ID
BK241074
Device Name
SeCore CDx HLA Sequencing System
Applicant
One Lambda, Inc. West Hills, CA
Product Code
QUK · Immunology
Decision Date
Aug 1, 2024
Decision
SESE
Regulation
21 CFR 866.5960
Device Class
Class 2
Attributes
Software as a Medical Device
Indications for Use
The SeCore CDx HLA Sequencing System is intended for the detection of human leukocyte antigen A-locus (HLA-A) alleles using genomic DNA isolated from whole blood samples. The device is intended to be used as a companion diagnostic (CDx) to aid in the selection of patients who may benefit from treatment or are likely to be at increased risk for serious adverse reactions because of treatment with therapies listed in the table below when used in accordance with approved therapeutic labeling. Indication(s): Unresectable or Metastatic Uveal Melanoma; HLA Target Allele(s): Eligible allele: HLA-A*02:01; Therapy: KIMMTRAK® (tebentafusp-tebn). Indication(s): Unresectable or Metastatic Synovial Sarcoma in Patients who have Received Prior Chemotherapy; HLA Target Allele(s): Eligible alleles: HLA-A*02:01, HLA-A*02:02, HLA-A*02:03 or HLA-A*02:06 and their P-group alleles; Exclusion alleles: HLA-A*02:05 and its P-group alleles; Therapy: TECELRA® (afamitresgene autoleucel).
Device Story
System uses sequence-based typing (SBT) to detect HLA-A alleles in genomic DNA from whole blood; utilizes PCR for locus-specific amplification followed by Sanger sequencing; fluorescent emission detection via BigDye Terminators. Data analyzed by uTYPE CDx HLA Sequence Analysis Software; compares sample sequences to IPD-IMGT/HLA database for allele assignment. Used in clinical laboratory settings; operated by trained laboratory personnel. Output provides HLA-A allele status to clinicians to aid in patient selection for specific therapies (KIMMTRAK or TECELRA). Benefits include identifying patients likely to benefit from or at risk of adverse reactions to targeted therapies.
Clinical Evidence
Clinical equivalence evaluated using 299 samples across three sites comparing SeCore Sequencing System to SSP UniTray/UniMatch Plus. Additional clinical trial data (IMCgp100-202 and ADP-0044-002) supported the companion diagnostic utility for patient selection. Analytical performance established via accuracy, precision, reproducibility, stability, and interference testing.
Technological Characteristics
Sequence-based typing (SBT) assay; genomic DNA input; PCR amplification; Sanger sequencing; fluorescent emission detection. Instrumentation includes Veriti™ Dx 96-Well Thermal Cycler and Applied Biosystems 3500 Dx/3500 xL Dx Genetic Analyzer. Software: uTYPE CDx HLA Sequence Analysis Software running on Windows 10 PC. Standardized database: IPD-IMGT/HLA.
Indications for Use
Indicated for patients with unresectable or metastatic uveal melanoma (HLA-A*02:01 positive) and patients with unresectable or metastatic synovial sarcoma who have received prior chemotherapy (HLA-A*02:01, HLA-A*02:02, HLA-A*02:03, or HLA-A*02:06 positive; HLA-A*02:05 negative).
Regulatory Classification
Identification
A human leukocyte antigen (HLA) typing companion diagnostic (CDx) test is a prescription genotyping or phenotyping in vitro diagnostic product intended for use as an aid in identifying patients who have specific HLA allele(s) or express specific HLA antigen(s) and may benefit from treatment with a corresponding therapeutic product or are likely to be at increased risk for serious adverse reactions as a result of treatment with a corresponding therapeutic product.
Special Controls
*Classification.* Class II (special controls). The special controls for this device are:(1) The intended use of the device must specify the target HLA allele(s) or antigen(s), the patient population(s), and the corresponding therapeutic product(s).
(2) Design verification and validation must include:
(i) Detailed documentation of an analytical accuracy study that uses well-characterized samples including clinical samples from intended use population(s) focusing on the target allele(s) needed for patient selection;
(ii) Detailed documentation of precision studies (repeatability, reproducibility) that evaluate possible sources of variation that may affect test results;
(iii) Detailed documentation of a study determining range of input sample concentrations that meet performance specifications;
(iv) Detailed description of the ambiguity resolution method, if applicable;
(v) For a sequencing-based assay, documentation of coverage and predefined coverage threshold of target genomic regions, pertinent variant types, and sequence contexts;
(vi) For multiplex assays, documentation of a risk assessment and design specifications that are in place to prevent incorrect reactivity assignment;
(vii) Description of a plan on how to ensure the performance of the device does not change when new HLA alleles are identified, and/or when reactivity assignments are changed; and
(viii) Detailed description of device software including standalone software, or software and bioinformatics analysis pipeline, if applicable, incorporated in the instruments, and documentation of software including the level of concern and associated risks, software requirement specifications, software design specifications (
*e.g.,* algorithms, alarms and device limitations), hazard analysis, traceability matrix, verification and validation testing, unresolved anomalies, hardware requirements, and effective cybersecurity management.(3) Clinical validity data (which may include summary reports from clinical trials, comparison studies using clinical samples, or through an alternative approach determined to be appropriate by FDA), demonstrating the following, as applicable:
(i) Which patients identified by the HLA CDx test are most likely to benefit from the corresponding therapeutic product; and
(ii) Which patients identified by the HLA CDx test are likely to be at increased risk for serious adverse reactions as a result of treatment with the corresponding therapeutic product.
(4) If the HLA test used in the clinical trials is different from the HLA CDx test in the premarket notification submission, the submission must include results of a bridging study, or an alternative approach determined to be appropriate by FDA.
Predicate Devices
SeCore™ CDx HLA Sequencing System (BR220737)
Reference Devices
SSP UniTray with UniMatch Plus interpretation software
{0}
ONE LAMBDA
A Thermo Fisher Scientific Brand
One Lambda, Inc.
22801 Roscoe Blvd.
West Hills, CA 91304
Tel 747.494.1000
Fax 747.494.1001
www.onelambda.com
## 510(k) SUMMARY
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of 21 CFR 807.92.
1. Submission Type: Traditional
2. Date Prepared: May 17, 2024
3. Submitter Information
Owner One Lambda, Inc.
22801 Roscoe Blvd
West Hills, CA 91304
Contact(s) Primary: Sheryl Skinner
Title: Director, Regulatory and Clinical Affairs
Address: One Lambda, Inc.
22801 Roscoe Boulevard
West Hills, CA 91304
USA
Tel: 1 (202) 415-5866
Email: sheryl.skinner@thermofisher.com
Alternate: Angela Estany
Title: Sr. Director, Regulatory Affairs and Quality
Address: One Lambda, Inc.
22801 Roscoe Boulevard
West Hills, CA 91304
USA
Tel: 1 (747) 494-1346
Email: angela.estany@thermofisher.com
Page 1 of 6
{1}
**ONE LAMBDA**^{}[] A Thermo Fisher Scientific Brand
One Lambda, Inc.^{}[] 22801 Roscoe Blvd.^{}[] ^{}[] West Hills, CA 91304^{}[] ^{}[] Tel 747.494.1000^{}[] ^{}[] Fax 747.494.1001^{}[] ^{}[] www.onelambda.com
#### 4. Device Information
| Product Code | Device Classification Name | Device Name | Submission Type/Number | Regulation Number | Class | Panel |
| --- | --- | --- | --- | --- | --- | --- |
| QUK | Human Leukocyte Antigen (Hla) Typing Companion Diagnostic Test | SeCore™ CDx HLA Sequencing System | Traditional BK241074 | 866.5960 | II | Immunology |
#### 5. Predicate Device:
| Product Code | Device Classification Name | Device Name | Submission Type/Number | Regulation Number | Class | Panel |
| --- | --- | --- | --- | --- | --- | --- |
| QUK | Human Leukocyte Antigen (Hla) Typing Companion Diagnostic Test | SeCore™ CDx HLA Sequencing System | Direct De Novo/ BR220737 | 866.5960 | II | Immunology |
#### 6. Device Description
The SeCore CDx HLA Sequencing System uses a sequence-based typing (SBT) method to detect HLA-A alleles in genomic DNA purified from whole blood specimens. SeCore CDx HLA Sequencing Kits directly identify the DNA sequence of target HLA genes. Polymerase chain reaction (PCR) is used with SeCore primers to perform locus-specific DNA amplification. Sanger sequencing is then used to determine the nucleotide sequence of the amplified product. Resulting data files are analyzed with uTYPE CDx HLA Sequence Analysis Software, which compares sample sequences to reference sequences in the IPD-IMGT/HLA database for HLA allele assignment.
#### 7. Intended Use and Indications for Use Statement
The SeCore CDx HLA Sequencing System is intended for the detection of human leukocyte antigen A-locus (HLA-A) alleles using genomic DNA isolated from whole blood samples. The device is intended to be used as a companion diagnostic (CDx) to aid in the selection of patients who may benefit from treatment or are likely to be at increased risk for serious
Page 2 of 6
{2}
ONE LAMBDA
A Thermo Fisher Scientific Brand
One Lambda, Inc.
22801 Roscoe Blvd.
West Hills, CA 91304
Tel 747.494.1000
Fax 747.494.1001
www.onelambda.com
adverse reactions because of treatment with therapies listed in the table below when used in accordance with approved therapeutic labeling.
Table 1: Proposed Indications for Use
| Indication(s) | HLA Target Allele(s) | Therapy |
| --- | --- | --- |
| Unresectable or Metastatic Uveal Melanoma | Eligible allele: HLA-A*02:01 | KIMMTRAK® (tebentafusp-tebn) |
| Unresectable or Metastatic Synovial Sarcoma in Patients who have Received Prior Chemotherapy | Eligible alleles: HLA-A*02:01, HLA-A*02:02, HLA-A*02:03 or HLA-A*02:06 and their P-group alleles Exclusion alleles: HLA-A*02:05 and its P-group alleles | TECELRA® (afamitresgene autoleucel) |
### 8. Nonclinical Studies
The SeCore CDx HLA Sequencing System has well established analytical performance characteristics from analytical studies conducted for 510(k)-clearance (refer to BK110038).
- Accuracy
- Precision, Reproducibility
- Stability
- Shipping/Transportation
- Detection Limit
- Sample Preparation
- Assay Cut-off
- Interference Testing
Two additional studies have been completed to support the SeCore CDx HLA Sequencing System for use as a companion diagnostic to ensure that the device is accurate within the target population and can effectively discriminate the required target allele(s).
- Detection of HLA-A*02:01 (KIMMTRAK®)
- Detection of HLA-A*02:01, HLA-A*02:02, HLA-A*02:03 or HLA-A*02:06 and their P-group alleles, excluding HLA-A*02:05 and its P-group alleles (TECELRA®)
Page 3 of 6
{3}
**ONE LAMBDA**^{}[] A Thermo Fisher Scientific Brand
One Lambda, Inc.
22801 Roscoe Blvd.
West Hills, CA 91304
Tel 747.494.1000
Fax 747.494.1001
www.onelambda.com
All test results demonstrated that subject device meets the requirements of its pre-defined acceptance criteria and intended use.
## 9. Clinical Testing
Samples from three testing sites (N=299) were tested to evaluate the equivalence between the SeCore Sequencing System and a predicate device (SSP UniTray with UniMatch Plus interpretation software). Test results demonstrated that subject device meets the requirements of its pre-defined acceptance criteria.
Additional companion diagnostic clinical trial studies were conducted using the SeCore CDx HLA Sequencing System for detection of human leukocyte antigen A-locus (HLA-A) alleles to aid in the selection of patients who may benefit from treatment with associated therapies. (Refer to Study Trials, IMCgp100-202 and ADP-0044-002)
## 10. Substantial Equivalence Determination
The device that is subject of the premarket notification submission has the same technological characteristics as the predicate device, the De Novo granted device previously cleared by FDA on November 28, 2022 (see BR220737).
A summary of the technological characteristics is as follows:
**Table 5: Comparison with Proposed Predicate Device**
| | Predicate Device (BR220737) | New Device (BK241074) |
| --- | --- | --- |
| **Device Name** | SeCore™ CDx HLA Sequencing System | Same |
| **Submission Number** | BR220737 | Pending |
| **Regulation Number** | 21 CFR 866.5960 | Same |
| **Regulation Name** | Human leukocyte antigen typing companion diagnostic test | Same |
Page 4 of 6
{4}
ONE LAMBDA
A Thermo Fisher Scientific Brand
One Lambda, Inc.
22801 Roscoe Blvd.
West Hills, CA 91304
Tel 747.494.1000
Fax 747.494.1001
www.onelambda.com
| | Predicate Device (BR220737) | New Device (BK241074) | | |
| --- | --- | --- | --- | --- |
| Classification | Class II | Same | | |
| Product Code | QUK | Same | | |
| Intended Use | The SeCore CDx HLA Sequencing System is intended for the detection of human leukocyte antigen A-locus (HLA-A) alleles using genomic DNA isolated from whole blood samples. The device is intended to be used as a companion diagnostic (CDx) to aid in the selection of HLA-A*02:01 positive patients with unresectable or metastatic uveal melanoma who may benefit from treatment with KIMMTRAK® (tebentafusp-tebn) when used in accordance with approved therapeutic labeling. | The SeCore CDx HLA Sequencing System is intended for the detection of human leukocyte antigen A-locus (HLA-A) alleles using genomic DNA isolated from whole blood samples. The device is intended to be used as a companion diagnostic (CDx) to aid in the selection of patients who may benefit from treatment or are likely to be at increased risk for serious adverse reactions because of treatment with therapies listed in the table below when used in accordance with approved therapeutic labeling: | | |
| | | Indication(s) | HLA Target Allele(s) | Therapy |
| | | Unresectable or metastatic Uveal Melanoma | Eligible allele: HLA-A*02:01 | KIMMTRAK® (tebentafusp-tebn) |
| | | Unresectable or Metastatic Synovial Sarcoma in Patients who have Received Prior Chemotherapy | Eligible alleles: HLA-A*02:01, HLA-A*02:02, HLA-A*02:03 or HLA-A*02:06 and their P-group alleles Exclusion alleles: HLA-A*02:05 and its P-group alleles | TECELRA® (afamitresgene autoleucel) |
| Indications for Use | For use in the Uveal Melanoma patient population. | For use in the unresectable or metastatic uveal melanoma and the unresectable or metastatic synovial sarcoma patient populations. | | |
| Assay Method | Sequence Based Typing | Same | | |
| Reactive Ingredient | Genomic DNA | Same | | |
Page 5 of 6
{5}
ONE LAMBDA
A Thermo Fisher Scientific Brand
One Lambda, Inc.
22801 Roscoe Blvd.
West Hills, CA 91304
Tel 747.494.1000
Fax 747.494.1001
www.onelambda.com
| | Predicate Device (BR220737) | New Device (BK241074) |
| --- | --- | --- |
| Specimen Type(s) | Whole Blood | Same |
| Sample Type(s) | Purified DNA | Same |
| Detection Reagents | Fluorescent emission detection from BigDye™ Terminators | Same |
| Software Technology | Uses personal computer. Operates with a Windows 10 operating system | Same |
| Software Main Components | uTYPE CDx HLA Sequence Analysis Software | Same |
| Instrumentation | DNA Amplification: Veriti™ Dx 96-Well Thermal Cycler Model 9912 with 0.2-mL sample wells (Class I Device) Capillary electrophoresis: Applied Biosystems 3500 Dx /3500 xL Dx Genetic Analyzer CS2 (Class 2 Device, 510(k)-cleared BK110039) | Same |
### 11. Conclusion
Analysis of the non-clinical, clinical, and safety and performance data concludes that the subject device SeCore CDx HLA Sequencing System is equivalent to the predicate device.
Page 6 of 6
Predicate graph will load when search results are available.
Embedding visualization will load when search results are available.
PDF viewer will load when search results are available.
Loading panels...
Select an item from Submissions
Click any panel, subpart, regulation, product code, or device to see details here.
Section Matches
Results will appear here.
Product Code Matches
Results will appear here.
Special Control Matches
Results will appear here.
Loading collections...
Loading
My Alerts
You will receive email notifications based on the filters and frequency you set for each alert.
Sort by:
Create Alert
Search Filters
Agent Token
Create a read-only bearer token for Claude, ChatGPT, or other agents that can call HTTP APIs.
Copy this now. It will not be shown again.
Connected apps
Apps you authorized through browser sign-in. Disconnecting revokes their access immediately.
Learn the FDA Browser
Two short videos show you everything — or skip straight to the written tutorial if you'd rather read. You can reopen this any time from the Tutorial button in the top bar.
Part 1 — Search, results, and everyday workflows 16 min
Part 2 — Embeddings: the galaxy map 3 min
1. Search: exact and fuzzy
Type a phrase like "coronary artery calcification" into the search box. You get two kinds of results. Exact results match the literal phrase — prefix searches work ("coronary artery calcificati") but suffix searches do not. Fuzzy results match on the meaning and intent of your phrase rather than the exact words, and are sorted by relevance score. Hover over the Exact or Fuzzy badge on any row to see exactly why it matched.
Use the checkboxes above the results to narrow: SaMD keeps only software-only devices, AI / ML keeps only devices with AI.
Exact vs. fuzzy search: what's the difference?
Exact matches on the literal phrase (prefix search works, suffix does not). Fuzzy matches on the meaning and intent of the phrase rather than the exact words. Hover over the badge on any row to see why it matched.
You search "coronary artery calcification" and want only software devices with AI. What two filters do you apply?
Narrow by SaMD (software-only devices), then narrow by AI/ML (devices with AI).
2. The results table
Scroll right in the results table. The intended use is extracted for you — no need to open the PDF. The device story gives a high-level snapshot of what the device does and how it's used. The AI Performance sub-table shows each output name, acceptance criteria, observed values, and development/test dataset descriptions — the same format Innolitics uses for regulatory strategy outputs, and the fastest high-level fingerprint of an AI device. It is AI-generated but has been very reliable in practice.
Where do you find a device's intended use without opening the PDF?
Scroll right in the search results table. The intended use column is extracted for you; no need to dig into the 510(k) summary PDF.
What does the AI Performance sub-table show, and why is it useful?
Output name, acceptance criteria, observed values, development dataset description, and test dataset description. It's the same format we use for regulatory strategy output and Fast 510(k) input, and the fastest high-level fingerprint of an AI device. AI-generated but reliable in practice.
3. Judging fuzzy relevance
Fuzzy results trail off in relevance as you scroll. Use three signals to decide how far down to go: the fuzzy badge explanations, the intended use column, and whether your target output (e.g., Cobb angle) still appears in the AI Performance sub-table. Once it stops appearing, you're past the relevant zone. A top hit with a low score (~0.4) and a stretched explanation is a hint the closest predicates are far away — the project may be headed for De Novo. Note the fuzzy search is a pattern match: it doesn't handle negation ("not") well, and hardware devices can appear — filter by SaMD/AI ML to cut them.
How do you judge how far down fuzzy search results to go?
Use the relevancy signals: the fuzzy badge explanations, the intended use column, and whether the target output (e.g., Cobb angle) still appears in the AI Performance sub-table. Once it stops appearing, results are trailing off in relevancy.
4. Device detail page: chat and citations
Click a device name to open its detail page: device facts on the left, a chat window on the right. Ask something like "Describe the training data". The answer carries little citation bubbles — click one to jump to the highlighted passage in the source PDF, so you can verify every AI answer against the document. There's also a Download PDF button for sharing.
How do you verify an AI chat answer on the device detail page?
Click the citation bubbles to jump to the relevant highlight in the source document.
Reading rule for every project: how many summaries do you read in full?
At least the three most relevant 510(k) or De Novo summaries, in full. After that, use targeted chat questions to confirm your memory quickly. The tool supports this professional habit — it doesn't replace it.
5. Side-by-side comparison
Select multiple rows in the results table (aim for under ~10), then open the PDF Viewer tab. Ask one question — it goes to all selected devices in parallel, each with citations. This is the fastest way to compare and contrast devices: training data, PCCP scope, how they handled adding new scanners, and so on.
What does the side-by-side PDF viewer mode do?
Select multiple devices, open the PDF viewer tab, and ask one question (e.g., "Describe the training data"). It queries all selected devices simultaneously with citations, so you can compare and contrast quickly.
6. Collections
With rows selected, go to the Collections tab and create a labeled collection (e.g., "Cobb Angle Project"). Reload that selection any time — before a client call, pull up the collection and ask questions across all of its devices at once.
How do you save a set of selected devices for later use?
Select the rows, go to the Collections tab, and create a labeled collection (e.g., "Cobb Angle Project"). You can reload the selection anytime and carry it into the PDF viewer and other tabs that support selections.
7. Product codes and the regulations tree
Click a product code in the results to jump to it in the regulations tree — identification text, sibling product codes, and devices you can open in a PDF viewer on the right. Click a regulation number to see its identification, special controls, and related product codes. You can also search by product code or regulation number at the top of the tree. Always read the special controls if any exist for your device — it broadens your search and sharpens pre-kickoff research.
What can you do from the regulations tree view?
Browse product codes and regulation numbers, read the identification text and special controls, browse sibling product codes, open device PDFs on the right, and search by product code or regulation number at the top of the tree.
8. Chart view
Click Show Chart and segment by regulation number (or product code) to see which regulations dominate your result set. Clicking a regulation takes you into the regulations tree. Great for spotting that most matches are, say, hardware laparoscopic devices — a cue to go back and filter.
How do you see which regulations dominate a search result set?
Click "Show Chart" and segment by Regulation Number. Clicking a regulation takes you to the regulations tree.
9. The predicate graph
Open the Predicates tab for a family-tree view of predicate relationships. Click a node to trace its parents and children; selections from search carry over pre-selected. Commonly predicated devices are worth reading — a lot of people predicated them for a reason. The visual lineage is also handy on client calls, e.g. to show how a predicate family evolved and justify why your predicate still holds.
In the predicate graph, why are commonly predicated devices worth reading?
A lot of people predicated them for a reason. Clicking a node traces parents and children, and selections from search carry over pre-selected.
10. Embeddings: the galaxy map
The Embeddings tab plots every matching document in a 2-D "galaxy map" where semantically similar devices cluster together. Hover or click clusters to explore, and let AI label the clusters for you. Embeddings beat product codes for grouping: two devices can carry different product codes (LLZ vs. QIH) yet do the same thing — the embedding captures the meaning of the intended use and device story. This is also exactly how retrieval-augmented generation (RAG) works under the hood, and it makes a great visual on client calls.
Try it yourself
Head to the search page and work through a few of these AI/ML fuzzy searches to build intuition: perivascular fat on CT · aortic valve calcification opportunistic screening on noncontrast CT · breast cancer prediction on digital pathology slides · autism detection · gestational age prediction · a hearing aid that can also detect a pulse · foundation model based analysis of ECG · large language models · penetration test. Watch how the relevance scores, intended use, and AI Performance tables tell you when results stop being meaningful.
